Correlation of Cyfra 21-1 levels in saliva and serum with CK19 mRNA expression in oral squamous cell carcinoma
- 158 Downloads
Oral squamous cell carcinoma (OSCC) accounts for 90 % of malignant lesions of oral cavity. The study assessed the potential of Cyfra 21-1 as a tumor marker in OSCC. The study included 50 patients of OSCC to evaluate levels of Cyfra 21-1 in serum and saliva by electrochemiluminescent immunoassay (ECLIA) and CK19 messenger RNA (mRNA) expression in tissue by florescent quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) along with healthy individuals as control. The salivary and serum Cyfra 21-1 levels in patients of OSCC were significantly higher compared to controls (p value < 0.01). There was a 2.75-fold increase in CK19 mRNA expression in OSCC cases compared to controls. A significant positive correlation was found between serum and salivary Cyfra 21-1, serum Cyfra 21-1, and CK19 mRNA expression and between salivary Cyfra 21-1 and CK19 mRNA expression. Among these, correlation between serum and salivary Cyfra 21-1 was highly significant. Salivary and serum Cyfra 21-1 showed significantly elevated levels in grade II OSCC compared to grade I histopathologically. Elevated levels of salivary Cyfra 21-1 were associated with recurrence in OSCC patients. Reverse operating curve constructed using 3 ng/ml as a cutoff for serum Cyfra 21-1 revealed the sensitivity and specificity to be 88 and 78.2 %, respectively. Using a cutoff value of 8.5 ng/ml for salivary Cyfra 21-1, the sensitivity was found to be 93.8 % and specificity 84.3 %. We advocate salivary Cyfra 21-1 as a better diagnostic marker over serum Cyfra 21-1 as well as a potential marker in the prognosis of OSCC.
KeywordsCyfra 21-1 Oral squamous cell carcinoma Cytokeratin19 Electrochemiluminescent immunoassay Polymerase chain reaction
Compliance with ethical standards
Ethics approval and consent to participate
The study protocol was approved by the Institutional Ethical Board Committee as a part of the research activities of the institute. Informed consent was taken from every patient participating in the study.
- 1.American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society 2007.Google Scholar
- 17.Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual, 7th ed. New York: Springer, 2010:29–35.Google Scholar
- 20.Doshi NP, Shah SA, Patel KB, Jhabuawala MF. Histological grading of oral cancer: a comparison of different systems and their relation to lymph node metastasis. Ntnl J Comm Med. 2011;2:136–42.Google Scholar
- 31.Sánchez-Carbayo M, Espasa A, Chinchilla V, Herrero E, Megías J, Mira A. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem. 1999;45:1944–53.PubMedGoogle Scholar